Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar
This article was originally published in The Gray Sheet
Executive SummaryFDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis
You may also be interested in...
Medtronic’s Endurant II AAA stent graft, Quest’s thyroid cancer test services and new Covidien Endo GIA staplers are among devices making market debuts.